Arabic Arabic English English French French German German
dark

Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates

Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

A comprehensive review of the antiviral potential of algal metabolites.

Next Post

Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy

Related Posts
Total
0
Share